

WHAT IS CLAIMED IS:

1. An improved method of treating B cell lymphoma which comprises administration of a therapeutic anti-CD20 antibody, wherein the improvement comprises administering at least one chemotherapeutic agent.
2. The method of Claim 1, wherein the antibody is a chimeric anti-CD20 antibody.
3. The method of Claim 1, wherein the chimeric antibody is C2B8.
4. The method of Claim 1, wherein the at least one chemotherapeutic agent is administered prior to antibody administration.
5. The method of Claim 1, wherein the at least one chemotherapeutic agent is administered simultaneous to antibody administration.
6. The method of Claim 1, wherein the at least one chemotherapeutic agent is administered after antibody administration.

7. The method of Claim 1, wherein the at least one chemotherapeutic agent is selected from the group consisting of cyclophosphamide, doxorubicin, vincristine, prednisone and mixtures thereof.

8. The method of Claim 7, wherein the at least one chemotherapeutic agent comprises a mixture of cyclophosphamide, doxorubicin, vincristine and prednisone, and the antibody is C2B8 or another anti-CD20 antibody that results in substantial depletion of peripheral B cells.

9. The method of Claim 8, wherein the antibody provides for nearly total peripheral blood B cell depletion within about 24 hours after administration.

10. The method of Claim 9, wherein the antibody dosage ranges from between about 0.4 and about 20 mg/kg body weight.

Add C'

add
E3